Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

D. M. O'Malley, A. Oaknin, B. J. Monk, A. Leary, F. Selle, J. Alexandre, L. M. Randall, C. Rojas, M. Neffa, A. Kryzhanivska, L. Gladieff, D. Berton, T. Meniawy, I. Lugowska, I. Bondarenko, K. N. Moore, W. I. Ortuzar Feliu, M. Ancukiewicz, I. Shapiro, I. L. Ray-Coquard

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

23 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S1164-S1165
Number of pages2
JournalAnnals of Oncology
Publication statusPublished - Sept 2020
EventESMO Virtual Congress -
Duration: 19 Sept 202018 Oct 2020

Cite this